Poddar Pawan, Podila Arvinda, Momin Majed Abdul Basit
Department of Cardiology, Yashoda Hospital, Hyderabad, Telangana, India.
Department of Laboratory Medicine, Yashoda Hospital, Hyderabad, Telangana, India.
Indian J Pharmacol. 2025 Sep 1;57(5):353-355. doi: 10.4103/ijp.ijp_124_25. Epub 2025 Aug 22.
Ticagrelor is an oral antiplatelet drug. The most common ticagrelor side effects include bleeding, dyspnea, bradycardia and in rare cases, microangiopathic hemolytic anemia. Isolated thrombocytopenia followed by a single-bolus dosage of ticagrelor is extremely uncommon. We encountered a 68-year-old male who had experienced rapid onset of chest pain and sweating for a day. The initial cardiac assessment suggested acute coronary syndrome and other laboratory tests, including a hemogram, were normal. The patient developed severe thrombocytopenia after receiving a loading dose of ticagrelor, despite the fact that no other thrombocytopenia-causing medicines were given to him. After discontinuing ticagrelor, the patient's platelet count gradually recovered with no need for additional transfusions or unnecessary investigations.
替格瑞洛是一种口服抗血小板药物。替格瑞洛最常见的副作用包括出血、呼吸困难、心动过缓，在极少数情况下还会出现微血管病性溶血性贫血。单次大剂量服用替格瑞洛后出现孤立性血小板减少极为罕见。我们遇到一名68岁男性，他胸痛和出汗一天，发病迅速。初步心脏评估提示急性冠状动脉综合征，包括血常规在内的其他实验室检查均正常。尽管未给该患者使用其他导致血小板减少的药物，但他在接受替格瑞洛负荷剂量后出现了严重血小板减少。停用替格瑞洛后，患者的血小板计数逐渐恢复，无需额外输血或进行不必要的检查。
